Product Description

iMatrix-511 Product SummaryLaminin 511 is known to bind to Intergin α6β1 of the cell surface. iMatrix-511 is highly purified human Laminin 511-E8 fragments recombinantly expressed by CHO-S cell.ApplicationiMatrix-511 can be used as cell culture matrix for various cell types including ES/iPS cells.ContentsLiquid Solution (175μg/vial @ 0.5 mg/mL Solvent: PBS(-)) .Product Size: 350μg (175μg x 2 pcs.)SpecificationsFormat: Solution (175μg/vial @ 0.5 mg/mL)Storage temperature: 2-15°CNaCl concentration: 137 mMActivityThe dissociation constant of the binding activity with integrin α6β1 is under 10 nM.

Procedure1. Dilute the solution with PBS (-). Coat dishes with 0.5μg/cm². The optimal coating concentration depends on cell lines from 0.1 to 1.5μg/cm². (For example, when you use 6-well plate (9.6 cm²/well), add 9.6μl iMatrix-511 (4.8ug) in 1.99ml of PBS(-). Add 2 mL of diluted iMatrix-511 solution to the well.)2. Incubate for 1 hour at 37°C, 3 hours at Room temperature, or over night at 4°C.3. Remove excess fluid from the coated surface. No rinse is needed.4. Immediately plate the cells at desired density.Notes:Don"t allow the plate to dry. Briefly spin down all liquid in the tube before use. Avoid repeated freeze-thaw cycles.DocumentationDownload Protocol [PDF]Download MSDS [PDF]Product Basics & StructureiMatrix-511 is an innovative cell culture matrix compatible with a wide variety of cell types, and exceptionally well suited for pluripotent stem cells. This product is comprised of recombinant Laminin-511 E8 protein fragments which permit ES/iPS cells to be maintained in xeno-free culture conditions, enable the passaging of single cells, and provide greater adhesion than full-length Laminin, Vitronectin or Matrigel⁵.Laminin-511 is a major component of the basement membrane used as a scaffold for pluripotent stem cells (ES/iPS cells), as it binds to integrin on cell surfaces. However Laminin-511 is a large protein (800kDa) composed of three chains (α-, β-, and γ-) forming a supramolecular aggregate, making it difficult to produce recombinantly. In order to overcome this challenge, Laminin-511 proteins were fragmented to find the smallest integrin-binding component and the E8 fragment was identified as the most promising result. In fact, hES cells were found to adhere more strongly to the E8 fragment than to the full-length protein.

In the same study cited above, Human ES cells were passaged on Laminin-511 E8 fragment and other cell culture substrates. Upon singly dispersing human ES cell colonies at the time of passage, it was confirmed that single cells adhere rapidly to Laminin-511 E8 and proliferate immediately.

Reference Literature

1. Miner, JH and Yurchenco, PD Laminin functions in tissue morphogenesis. Annu. Rev. Cell Dev. Biol. 20, 255-284 (2004).https://doi.org/10.1146/annurev.cellbio.20.010403.0945552. Ido H, Harada K, Futaki S, Hayashi Y, Nishiuchi R, Natsuka Y, Li S, Wada Y, Combs AC, Ervasti JM and Sekiguchi K. Molecular dissection of the alpha-dystroglycan- and integrin-binding sites within the globular domain of human laminin-10. J. Biol. Chem. 279, 10946-10954 (2004).https://doi.org/10.1074/jbc.M3136262003. Ido H, Nakamura A, Kobayashi R, Ito S, Li S, Futaki S and Sekiguchi K. The requirement of the glutamic acid residue at the third position from the carboxyl termini of the laminin gamma chains in integrin binding by laminins. J. Biol. Chem. 282, 11144-11154 (2007).https://doi.org/10.1074/jbc.M6094022004. Taniguchi Y, Ido H, Sanzen N, Hayashi M, Sato-Nishiuchi R, Futaki S and Sekiguchi K. The C-terminal region of laminin beta chains modulates the integrin binding affinities of laminins. J. Biol. Chem. 284, 7820-7831 (2009).https://doi.org/10.1074/jbc.M8093322005. Miyazaki T, Futaki S, Suemori H, Taniguchi Y, Yamada M, Kawasaki M, Hayashi M, Kumagai H, Nakatsuji N, Sekiguchi K and Kawase E. Laminin E8 fragments support efficient adhesion and expansion of dissociated human pluripotent stem cells. Nat. Commun. 3, 1236 (2012).https://doi.org/10.1038/ncomms22316. Nakagawa M, Taniguchi Y, Senda S, Takizawa N, Ichisaka T, Asano K, Morizane A, Doi D, Takahashi J, Nishizawa M, Yoshida Y, Toyoda T, Osafune K, Sekiguchi K, Yamanaka S. A novel efficient feeder-free culture system for the derivation of human induced pluripotent stem cells. SCIENTIFIC REPORTS | 4 : 3594 | doi:10.1038/srep035947. Yasuhiro Takashima, Ge Guo, Remco Loos, Jennifer Nichols, Gabriella Ficz, Felix Krueger, David Oxley, Fatima Santos, James Clarke, William Mansfield, Wolf Reik, Paul Bertone, Austin Smith Resetting Transcription Factor Control Circuitry toward Ground-State Pluripotency in Human. Cell Volume 158, Issue 6, p1254–1269, 11 September 2014 doi:10.1016/j.cell.2014.08.0298. Doi D et al. (2014). Isolation of Human Induced Pluripotent Stem Cell-Derived Dopaminergic Progenitors by Cell Sorting for Successful Transplantation.Stem Cell Reports. 2 (3): 337-50.https://doi.org/10.1016/j.stemcr.2014.01.0139. Takashima Y et al. (2014). Resetting Transcription Factor Control Circuitry toward Ground-State Pluripotency in Human. Cell. 158 (6): 1254-69.https://doi.org/10.1016/j.cell.2014.08.02910. Fukuta M et al. (2014). Derivation of mesenchymal stromal cells from pluripotent stem cells through a neural crest lineage using small molecule compounds with defined media.PLos One. 9 (12) : e112291.https://doi.org/10.1371/journal.pone.011229111. Hayashi et al. (April 2015). Structure-based discovery of NANOG variant with enhanced properties to promote self-renewal and reprogramming of pluripotent stem cells. PNAS vol. 112 (15): 4666-4671.https://doi.org/10.1073/pnas.1502855112

FOR RESEARCH USE ONLY, NOT FOR USE IN DIAGNOSTIC PROCEDURES.

Manufactured by: Nippi, Inc.*License to manufacture and sell this product has been obtained from Osaka University & Kyoto University.*

Iwai-Chem我们的合作伙伴公司Bio Matrix Research，Inc.（BMR）正在申请专利，CELIXSYS™是一种新颖的单克隆抗体筛选方法（免疫沉淀等效系统），可保持抗原构象完整且表位不受空间位阻。  通过克服传统的基于固相的筛选方法（例如抗原包被的ELISA，斑点印迹或蛋白质印迹）的缺点，CELIXSYS™使我们能够获得适用于各种应用的卓越单克隆抗体，例如高灵敏度夹心ELISA，免疫色谱法或抗体阵列系统，以及免疫沉淀和蛋白质印迹。CELIXSYS™使得开发有益的单克隆抗体成为可能，而迄今为止，传统方法尚无法实现。展望未来，这项新技术的应用领域将继续从基础研究和临床诊断试剂扩展到抗体药物的探索。